Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 7/20 | 0.67 |
| ▸ | AKR1C2 | P52895 | 6/20 | 0.67 |
| ▸ | PTGS2 | P35354 | 6/20 | 0.66 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.66 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.66 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.66 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.63 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.63 |
| ▸ | TSHR | P16473 | 1/20 | 0.63 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.63 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.63 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8647232 | 0.90 | AKR1C3 (0.78) | AKR1C3AKR1C2PTGS2AKR1C4AKR1C1 | |
| SCHEMBL5801150 | 0.88 | AKR1C3 (0.87) | AKR1C3AKR1C2PTGS2AKR1C4AKR1C1 | |
| SCHEMBL17354682 | 0.83 | PTGS1 (0.84) | AKR1C3AKR1C2PTGS2AKR1C4AKR1C1 | |
| SCHEMBL19861551 | 0.83 | AKR1C3 (0.74) | AKR1C3AKR1C2PTGS2AKR1C4AKR1C1 | |
| SCHEMBL18271385 | 0.83 | AKR1C3 (0.82) | AKR1C3AKR1C2PTGS2AKR1C4AKR1C1 | |
| SCHEMBL15215990 | 0.83 | AKR1C3 (0.79) | AKR1C3AKR1C2PTGS2AKR1C4AKR1C1 | |
| SCHEMBL8356332 | 0.82 | PTGS2 (0.59) | AKR1C3PTGS2PTGS1 | |
| SCHEMBL20349624 | 0.82 | PTGS2 (0.83) | AKR1C3AKR1C2PTGS2AKR1C4AKR1C1 | |
| SCHEMBL24969903 | 0.81 | AKR1C3 (0.68) | AKR1C3AKR1C2PTGS2AKR1C4AKR1C1 | |
| SCHEMBL860853 | 0.81 | PTGS2 (0.80) | AKR1C3AKR1C2PTGS2AKR1C4AKR1C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230023607-A1 | METHODS FOR PRACTICAL SYNTHESIS OF DEUTERATED AMINO ACIDS | NATIONAL INSTITUTES OF HEALTH | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230023607-A1 | METHODS FOR PRACTICAL SYNTHESIS OF DEUTERATED AMINO ACIDS | DAO, DDO, DDOST | AKR1C3 4582/4885AKR1C2 4449/4885PTGS2 4531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.